Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Bonfim, Carmem  [Clear All Filters]
2023
Belbachir S, Abraham A, Sharma A, Prockop S, DeZern AE, Bonfim C, Bidgoli A, Li J, Ruggeri A, Bertaina A, et al. Engineering the best transplant outcome for high-risk acute myeloid leukemia: the donor, the graft and beyond. Cytotherapy. 2023.
Gurnari C, Robin M, Godley LA, Drozd-Sokołowska J, Włodarski MW, Raj K, Onida F, Worel N, Ciceri F, Carbacioglu S, et al. Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT. Lancet Haematol. 2023.
Nichele S, Bonfim C, Junior LGD, Loth G, Kuwahara C, Trennephol J, Funke VAM, Marinho DE, Koliski A, Rodrigues AM, et al. Hematopoietic cell transplantation for telomere biology diseases: A retrospective single-center cohort study. Eur J Haematol. 2023.
Garcia-Rosa M, Abraham A, Bertaina A, Bhoopalan SVelan, Bonfim C, Cohen S, Dezern A, Louis C, Oved J, Pavel-Dinu M, et al. International society for cell & gene therapy stem cell engineering committee: Cellular therapies for the treatment of graft-versus-host-disease after hematopoietic stem cell transplant. Cytotherapy. 2023.
Nassani M, Fakih REl, Passweg J, Cesaro S, Alzahrani H, AlAhmari A, Bonfim C, Iftikhar R, Albeihany A, Halkes C, et al. The role of androgen therapy in acquired aplastic anemia and other bone marrow failure syndromes. Front Oncol. 2023;13:1135160.
Klein OR, Bonfim C, Abraham A, Ruggeri A, Purtill D, Cohen S, Wynn R, Russell A, Sharma A, Ciccocioppo R, et al. Transplant for non-malignant disorders: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee report on the role of alternative donors, stem cell sources and graft engineering. Cytotherapy. 2023.
2020
Arcuri LJavier, Nabhan SKanaan, Loth G, Atta EHallack, Oliveira M, Nichele S, Araujo Rde Castro, Bonfim C. A case series of post-transplant cyclophosphamide in unrelated donor hematopoietic transplantation for aplastic anemia. Biol Blood Marrow Transplant. 2020.
Marinho DHespanha, Ribeiro LLima, Nichele S, Loth G, Koliski A, Mousquer RToassa Gom, Funke VAraújo Mo, Page K, Fasth A, Pasquini R, et al. The challenge of long-term follow-up of survivors of childhood acute leukemia after hematopoietic stem cell transplantation in resource-limited countries: A single-center report from Brazil. Pediatr Transplant. 2020:e13691.
Arcuri LJavier, Nabhan SKanaan, Cunha R, Nichele S, Ribeiro AAlice Feit, Fernandes JFolloni, Daudt LEsteves, Rodrigues ALuiza Melo, Arrais-Rodrigues C, Seber A, et al. Impact of CD34 cell dose and conditioning regimen on outcomes after Haploidentical donor hematopoietic stem cell transplantation with post-transplant cyclophosphamide for relapsed/refractory severe aplastic anemia: Haploidentical HCT with PTCy for SAA. Biol Blood Marrow Transplant. 2020.
Arnold SD, Brazauskas R, He N, Li Y, Hall M, Atsuta Y, Dalal J, Hahn T, Khera N, Bonfim C, et al. The impact of donor type on outcomes and cost of allogeneic hematopoietic cell transplant for pediatric leukemia: a merged CIBMTR and PHIS analysis: Pediatric acute leukemia transplant risks and utilization. Biol Blood Marrow Transplant. 2020.
Fernandes JFolloni, Nichele S, Arcuri LJavier, Ribeiro L, Netto GZamperlini, Loth G, Rodrigues ALuiza Melo, Kuwahara C, Koliski A, Trennepohl J, et al. Outcomes after Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Patients with Primary Immunodeficiency Diseases. Biol Blood Marrow Transplant. 2020.